Integrase inhibitors and interventions directed toward DNA-PK might improve T-cell survival and immune function during human immunodeficiency virus-1 infection.40 One DNA-PK inhibitor has been developed as an anti-cancer agent on the basis of its ability to potentiate cell death mediated by chemotherapy- and radiation therapy-induced DSBs, thus suggesting that DNA-PK coupled with small molecule pharmacological inhibitors might be developed as a novel treatment approach for patients with T cell-associated malignancies. Here, PRKDC is linked to cancer.